LncRNA GAS6-AS2 promotes non-small-cell lung cancer cell proliferation via regulating miR-144-3p/ MAPK6 axis

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
   PubMed Web of Science ®Google Scholar
• Graham MV, Purdy JA, Emami B, et al. Clinical dose–volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol* Biol* Phys. 1999;45(2):323–329. .
   PubMed Web of Science ®Google Scholar
• Zhang J-G, Wang -J-J, Zhao F, et al. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010;411(11–12):846–852.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer. J clin oncol. 2003;21(12):2237–2246. .
   PubMed Web of Science ®Google Scholar
• Peters S, Adjei A, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl_7):vii56–vii64. .
   PubMed Web of Science ®Google Scholar
• Nie W, Ge H-J, Yang X-Q, et al. LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett. 2016;371(1):99–106. .
   PubMed Web of Science ®Google Scholar
• Gibb EA, Vucic EA, Enfield KS, et al. Human cancer long non-coding RNA transcriptomes. PloS One. 2011;6(10):e25915. .
   PubMed Web of Science ®Google Scholar
• Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochimica Et Biophysica Acta (Bba)-gene Regulatory Mechanisms. 2014;1839(11):1097–1109.
   PubMed Web of Science ®Google Scholar
• Hu Z, Chen J, Tian T, et al. Genetic variants of miRNA sequences and non–small cell lung cancer survival. J Clin Invest. 2008;118(7):2600–2608. .
   PubMed Web of Science ®Google Scholar
• Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11):3753–3756. .
   PubMed Web of Science ®Google Scholar
• Tanabe H, Yagihashi A, Tsuji N, et al. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer. 2004;46(3):299–304.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Moriyama S, Nakashima Y, et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer. 2004;46(2):171–178. .
   PubMed Web of Science ®Google Scholar
• Wu F, Mo Q, Wan X, et al. NEAT1/hsa‐mir‐98‐5p/MAPK6 axis is involved in non–small‐cell lung cancer development. J Cell Biochem. 2019;120(3):2836–2846.
   PubMed Web of Science ®Google Scholar
• Bian K, Muppani NR, Elkhadragy L, et al. ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells. Oncotarget. 2016;7(6):6665. .
   PubMedGoogle Scholar
• WEINHÄUSEL A Lung cancer diagnostic method and means. Google Patents; 2018.
   Google Scholar
• Long W, Foulds CE, Qin J, et al. ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 2012;122(5):1869–1880. .
   PubMed Web of Science ®Google Scholar
• Yang JH, Li JH, Shao P, et al. starBase: a database for exploring microRNA-mRNA interaction maps from argonaute CLIP-Seq and degradome-Seq data. Nucleic Acids Res. 2011;39(Databaseissue):D202–9.
   PubMed Web of Science ®Google Scholar
• Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4. DOI:10.7554/eLife.05005
   Web of Science ®Google Scholar
• Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48(D1):D127–D31.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhao Y, Li F, et al. MiR-144-3p: a novel tumor suppressor targeting MAPK6 in cervical cancer. J Physiol Biochem. 2019;75(2):143–152.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. .
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028. .
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wang J, Wang S, et al. LncRNA CCAT2 promotes tumorigenesis by over-expressed Pokemon in non-small cell lung cancer. Biomed Pharmacother. 2017;87:692–697.
   PubMed Web of Science ®Google Scholar
• Shao Y, Ye M, Li Q, et al. LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer. Oncotarget. 2016;7(25):37812. .
   PubMedGoogle Scholar
• Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochimica Et Biophysica Acta (Bba)-gene Regulatory Mechanisms. 2016;1859(1):169–176.
   PubMed Web of Science ®Google Scholar
• Pillai RS, Artus CG, Filipowicz W. Tethering of human Ago proteins to mRNA mimics the miRNA-mediated repression of protein synthesis. Rna. 2004;10(10):1518–1525.
   PubMed Web of Science ®Google Scholar
• Ballantyne M, McDonald R, Baker A. lncRNA/MicroRNA interactions in the vasculature. Clin Pharmacol Ther. 2016;99(5):494–501.
   PubMed Web of Science ®Google Scholar
• Li S, Mei Z, Hu HB, et al. The lncRNA MALAT1 contributes to non‐small cell lung cancer development via modulating miR‐124/STAT3 axis. J Cell Physiol. 2018;233(9):6679–6688.
   PubMed Web of Science ®Google Scholar
• Tan J, Yang L, Liu C, et al. MicroRNA-26a targets MAPK6 to inhibit smooth muscle cell proliferation and vein graft neointimal hyperplasia. Sci Rep. 2017;7:46602.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Wang S, Xiang Y. Up-regulated microRNA499a by hepatitis B virus induced hepatocellular carcinogenesis via targeting MAPK6. PloS One. 2014;9(10):e111410.
   PubMed Web of Science ®Google Scholar